$15 million in Series A investment was raised by Allozymes, a Singapore-based pioneer in the discovery and engineering of enzymes.
Investors
- Xora Innovation from Singapore
- Seventure Partners from France
Use of funds
With the money, the business plans to expand into Europe more quickly, create strategic alliances in the food and chemical industries, and establish new alliances in the pharmaceutical and life science sectors.
“This investment is a testament to our progress in developing a truly unique and powerful enzyme engineering platform. Our goal is to fully use enzymes in order to create a more effective and sustainable future.”
Peyman Salehian
About Allozymes
Allozymes is a biotechnology business led by CEO Peyman Salehian that uses its patented platform technology to quickly generate new enzymes and advance the bioeconomy in a variety of industries. It seeks to create an enzyme data library by utilizing this screening capacity in order to meet present and future requirements for developing reliable biosolutions.
